In the quarter ended September 30, California-based Foresite Capital Management VI fully liquidated its position in Edgewise Therapeutics by selling 585,000 shares, representing approximately $7.67 million based on the quarter’s average trading levels. Prior to the sale, Edgewise comprised about 4.3% of the fund’s assets under management; following the exit, the fund reported zero remaining shares. This move marked one of the largest single holdings reductions for Foresite during a period of heightened biotech market volatility.

Following the exit, Foresite’s top five equity positions included Congenica at $89.48 million (34.6% of AUM), RAPT Therapeutics at $40.30 million (15.6%), Centessa Pharmaceuticals at $31.86 million (12.3%), Verastem Oncology at $23.09 million (8.9%), and Alms Therapeutics at $16.95 million (6.5%). The reallocation underscores a shift in exposure away from prolonged clinical timelines toward assets with nearer-term catalysts or diversified risk profiles within the early-stage biotech space.

As of the latest reporting period, Edgewise Therapeutics held approximately $563 million in cash and marketable securities against a negative trailing-twelve-month net income of $157.24 million. Third-quarter R&D expenditures drove a net loss of $40.7 million as the company advanced multiple clinical programs—including late-stage testing of its lead small-molecule candidate in muscular dystrophy and expansion into cardiac indications. With no commercial revenues to date, the firm remains a clinical-stage biopharma focused on precision therapies for rare neuromuscular diseases.

Among ten recent equity research reports, one analyst rated the stock as a Strong Buy, six as Buy, three as Hold and one as Sell, yielding a consensus of Moderate Buy. While some firms have increased their outlook based on the company’s cash runway and pipeline progress, others have flagged the absence of imminent commercial milestones as a key risk, reflecting a balanced yet cautious investor stance.